GlassScriptPhysician profile
Morgan Callahan
NPI 1932593266
$3,622.88
in general payments reported to CMS, 2019-2025
31 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $422 · 2021: $626 · 2022: $332 · 2023: $436 · 2024: $537 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.75 | 2021-2025 | Botox, Ubrelvy |
| Medtronic USA, INC. | $548.74 | 2019-2020 | |
| Abbott Laboratories | $537.80 | 2019-2024 | Proclaim |
| Allergan, INC. | $178.98 | 2020-2022 | |
| Davol INC. | $142.86 | 2024 | Arista Ah Flexitip |
| Boston Scientific Corporation | $124.84 | 2019 | |
| Pfizer INC. | $122.04 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $96.00 | 2022-2024 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $95.67 | 2022 | |
| Fidia Pharma USA INC. | $66.56 | 2020-2024 | Hymovis, Triluron, Hyalgan |
| Biohaven Pharmaceuticals, INC. | $63.92 | 2021 | |
| Forte Bio-Pharma LLC | $63.40 | 2024 | Prolate, Nalocet |
| Almatica Pharma LLC | $62.35 | 2021-2022 | |
| Bioventus LLC | $60.57 | 2023-2025 | Durolane, Supartz Fx Sodium Hyaluronate |
| Scilex Pharmaceuticals INC. | $47.34 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $39.44 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $39.34 | 2022-2023 | Seglentis |
| Pacira Therapeutics, INC. | $34.86 | 2021 | |
| Ibsa Pharma INC. | $33.47 | 2021 | |
| Biodelivery Sciences International, INC. | $32.04 | 2020-2021 | |
| Si-Bone, INC. | $31.05 | 2024 | |
| Stryker Corporation | $27.67 | 2021 | |
| Averitas Pharma INC. | $27.27 | 2023 | Qutenza |
| Lundbeck LLC | $27.18 | 2023 | Vyepti |
| Spr Therapeutics, INC | $24.75 | 2024 | Sprint Pns System |
| Nalu Medical, INC. | $24.57 | 2025 | Nalu Neurostimulation System |
| Coastal Medical Technologies LLC | $22.18 | 2025 | |
| Tonix Medicines, INC. | $22.05 | 2025 | Tonmya |
| Curonix LLC | $15.23 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Redhill Biopharma INC. | $14.01 | 2021 | |
| Hikma Pharmaceuticals USA | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.